Ischemia modified albumin (IMA), as measured using the albumin cobalt binding test, is
currently the most promising biomarker for early detection of ischemia before the onset of …

Cardiovascular disease (CVD) is the single greatest cause of adult mortality in the western
world and, consequently, places a massive burden on healthcare services and the …

The diagnosis of cardiac ischemia remains a challenge in contemporary emergency
medicine. A blood-borne biomarker is an attractive alternative to cardiac imaging or stress …

First identified in the early 1990s, IMA is produced when ischemia stresses released from
hypoxic heart tissue induce modification of circulating albumin. 5, 6 The amino terminal end …

The diagnostic approach to acute myocardial infarction (AMI) is still one of the most
challenging and controversial medical issues. Although the measurement of cardiospecific …

Methods for detecting estradiol and metabolites thereof in a sample are provided. A plurality
of particles, each of which is coated with a capture agent having an affinity forestradiol, is …

BACKGROUND: Little is known about the capacity of ischemia-modified albumin (IMA)
plasma concentration to predict long-term cardiac outcome in patients with established …

Background: Ischemia-modified albumin has been proposed as a useful rule-out marker for
the diagnosis of acute coronary syndrome in the emergency department. Objective: To …

Ischemia modified albumin (IMA) is a relatively new marker for evaluating patients with
cardiac ischemia. Data are emerging on its potential role in non-cardiac ischemic events. In …

Objective. We examined serum ischaemia-modified albumin (IMA) levels in normal pregnant
and preeclamptic women. The primary aim of our study was to assess IMA in women with …